Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703 Supported in part by University of Colorado Shared Resources ...

Researchers assess the cost‐effectiveness of nivolumab plus ipilimumab vs lenvatinib or sorafenib for hepatocellular carcinoma from a US healthcare payer perspective.

Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC. This is an ASCO Meeting Abstract from the 2022 ASCO ...

The immunotherapy combination was initially more costly but resulted in a lower cost of care over a 2-year period, investigators found. The immunotherapy combination of nivolumab (Opdivo) and ...

A Prescription Drug User Fee Act target date of April 21, 2025 has been assigned to the application. Findings showed the immunotherapy combination significantly improved overall survival (OS; primary ...

The median duration of recurrence-free survival was 61.1 and 24.2 months with nivolumab and ipilimumab, respectively, at a minimum follow-up of 107 months. HealthDay News — For patients with resected ...

Please provide your email address to receive an email when new articles are posted on . The addition of nivolumab to ipilimumab prolonged survival for patients with advanced melanoma. Nivolumab ...

Please provide your email address to receive an email when new articles are posted on . Nivolumab significantly improved RFS for advanced melanoma compared with ipilimumab after 9 years of follow-up.

Final results from the TITAN-RCC trial demonstrate improvements in objective response rates compared with nivolumab monotherapy. Adaptive treatment with nivolumab plus ipilimumab improves outcomes ...

Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte–associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary activity ...

Using a lower dose of melanoma immunotherapy may extend survival while reducing dangerous side effects. New research suggests that reducing the dose of a commonly used immunotherapy for malignant ...

Credit: Thinkstock Study revealed an objective response rate consistent with that observed in the CheckMate 214 clinical trial and a low rate of treatment-related adverse events. Real-world data ...